PanOptica Company

Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.

Investors

Founded Date: 1-1
Total Funding: $95.2M
Investor Type: For Profit
Employee Number: 101-250
Funding Status: Early Stage Venture
Technology: P4 Medicine
Last Funding Type: Venture - Series Unknown
Investors Number: 10
Industry: Biopharma, Biotechnology, Therapeutics
Headquarters: Mount Arlington, New Jersey, United States
Estimated Revenue: $1M to $10M
Register and Claim Ownership